Support from Non-Clinical Stage to Product Approval
Goal to Obtain Phase 1 Clinical Trial IND Approval This Year
GC Green Cross announced on the 17th that it has been selected for the "Pandemic Preparedness mRNA Vaccine Development Support Project," promoted by the Korea Disease Control and Prevention Agency to secure a domestic mRNA (messenger ribonucleic acid) vaccine platform.
This project aims to develop an mRNA vaccine platform to ensure stable vaccine supply in preparation for pandemics. The government will support the entire process from the non-clinical stage of mRNA vaccines to product approval, with a total investment of 505.2 billion KRW from 2025 to 2028.
This year, as the initial entry phase of the project, the Disease Control Agency plans to support non-clinical research by selected companies. GC Green Cross stated that it aims to secure non-clinical trial results in animals this year and obtain approval for the clinical trial plan (IND) for Phase 1 clinical trials.
As a leading domestic vaccine developer, GC Green Cross has established a dedicated research team for mRNA and lipid nanoparticles (LNP) since 2019 and has continued related research. The team has currently built proprietary core technologies such as the mRNA platform and LNP, and based on this, plans to develop a COVID-19 mRNA vaccine with excellent safety and immunogenicity.
GC Green Cross has also completed preparations for mRNA production facilities. In 2023, it established an mRNA-LNP manufacturing plant in Hwasun, Jeollanam-do, where the vaccine factory is located, equipped with facilities capable of developing all processes using in-house technology.
A GC Green Cross official said, "Based on our extensive experience in successfully domesticating many vaccines, we intend to accelerate mRNA vaccine development," adding, "We plan to create opportunities for next-generation domestic mRNA vaccine research based on our proven vaccine platform technology."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
